Results · Apr-Jun 2026
Mankind Pharma Q1 FY27 results
StrongStrong: sales up 10% or more & profit up 20% or more on the same quarter last year, with a wider operating margin.
Sales grew 13% to ₹4,031 crore from ₹3,570 crore in Apr-Jun 2025.
Operating profit grew 25% to ₹1,056 crore, an operating margin of 26.2% (up 2.5 points from a year ago).
Net profit grew 29% to ₹574 crore from ₹445 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +17%, net profit +3%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 4,031 | 3,570 | +13% |
| Operating profit (EBITDA) | 1,056 | 846.8 | +25% |
| Operating margin | 26.2% | 23.7% | +2.5 pts |
| Net profit | 574.1 | 444.6 | +29% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.